Trial Profile
A Phase 1, Open-label, Multiple-dose Study of KHK4827 in Subjects With Systemic Sclerosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kyowa Kirin
- 20 Dec 2022 Planned End Date changed from 31 Dec 2022 to 29 Feb 2024.
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism
- 01 Jun 2022 According to Kyowa Kirin media release, abstract containing data from this trial are available on the EULAR Congress website